Sanofi/Regenerative PD-1 monoantia Libtayo shows significant benefits in base cell carcinoma
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sanofi and regenerative PD-1 monolibalibalib (cemiplimab) show a 'clinically meaningful and long-lasting response' in base cell carcinoma (BCC), which currently has no approved treatmentThe two companies released key data from a key single-arm open label trial in which advanced BCC patients were intolerant of disease progression or intolerance after treatment of the hedgehog inhibitor (HHI)in this trial, the objective remission rate (ORR) after Libtayo treatment was 29 percent for patients with advanced local BCC, and in 85 percent of the remission soutcomed duration (DOR) for more than one yearThe persistent disease control rate (DCR: a stable disease that alleviates or lasts at least 6 months) is 60%although the vast majority of BCC is discovered early and can be cured by surgery or radiation, a small number of tumors develop into late stages and penetrate deeper into the surrounding tissue (local late stage), making it difficult to treatLibtayo has received initial approval in the United States for advanced skin squamous cell carcinoma (CSCC) in 2018Sanofi and Regeneration are scheduled to file regulatory filings in 2020
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
